Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes
Agenus’ lead clinical programs include:
AGEN1181 (our multipurpose, next-generation CTLA-4)1: Unprecedented early clinical responses; among first 21 evaluable patients treated with AGEN1181 monotherapy, 1 CR in aggressive endometrial cancer, 1 PR in melanoma. Among first 31 evaluable patients treated with AGEN1181 + balstilimab, 1 CR by PET in aggressive endometrial cancer, 1 CR and 1 PR in ovarian cancer, 2 PRs in CRC.
AGEN2373 in clinical development: a CD137 agonist with unique properties designed to impart memory immune response without the toxicities of other CD137 targeting antibodies
AgenT-797 in clinical development2: Invariant natural killer T (iNKT) cell based therapy that combines features of two critical arms of the immune system, T cells (adaptive immunity) and NK cells (innate immunity), making them invaluable in combating diseases like COVID-19 and cancer
AGEN1777 in clinical development3: a first-in-class TIGIT bispecific to target a major inhibitory receptor expressed on T and NK cells to improve anti-tumor activity
Balstilimab in second-line cervical cancer4: 20% ORR in PD-L1 (+) patients; ~40% improvement to pembrolizumab. ORR of 15% in all-comers, with a median duration of response of 15.4 months
Balstilimab (anti PD-1) + zalifrelimab (anti CTLA-4) in second-line cervical cancer5: 33% ORR in PD-L1 (+) patients; 26% ORR in all-comers; expands benefit of anti-PD-1 alone